|Articles|November 21, 2017

On a Technology Enabled Collison Course

External Link - ICON_Whitepaper_RWE_Technology-Aug2017.pdf

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Trending on PharmExec

On a Technology Enabled Collison Course

Related Content

The New Healthy Aging Imperative and What It Means for Pharma

Reading Between the Lines: Closing the T1D Misdiagnosis Gap

Pharmaceutical Executive Daily: FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer

Beyond the Strip: Las Vegas Has a New Kind of Venture in Mind

Novartis Announces $105 Million Collaborative Agreement with Antares Therapeutics

Trending on PharmExec

FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer

The Rise of Direct-to-Patient Models in Pharma: Opportunities and Risks in Bypassing Traditional Distribution Channels

Novartis Announces $105 Million Collaborative Agreement with Antares Therapeutics

Ibrance Wins FDA Approval for HR-Positive, HER2-Positive Metastatic Breast Cancer Maintenance Therapy

Pharmaceutical Executive Daily: FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer